Boston-based Full Circles Therapeutics and circular RNA developer Circio have inked a research collaboration focused on efficient and redosable nonviral gene therapies.
The collaboration will evaluate the combination of Circio’s circVec expression technology with Full Circles’ C4DNA, a novel minicircular single-stranded DNA (cssDNA) for in vivo cell therapy. The goal is to create a nonviral, non-integrating and immune silent in vivo cell therapy platform, designed to be safe, durable and redosable.
“Our C4DN platform is designed to enable immune-evasive DNA modality with the capacity to deliver extra-larger genetic payloads, while Circio’s circVec technology has demonstrated the potential for increased and durable expression,” said Howard Wu, Ph.D., co-founder and CSO of Full Circles Therapeutics. “Together, we aim to develop a differentiated, nonviral platform for in vivo cell engineering that could enable durable and redosable therapies while offering the manufacturing and safety advantages of DNA-based delivery.”
Read more about Circio’s work in circular RNA in our cover story, RNA’s comeback tour.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!